Avanir Pharmaceuticals inks co-promotion deal with Merck on Januvia

|About: Avanir Pharmaceuticals, Inc (AVNR)|By:, SA News Editor

Avanir Pharmaceuticals (AVNR) ramps higher in the post-session after saying it's entered into an exclusive, multi-year agreement with Merck (MRK) to co-promote MRK's type 2 diabetes therapies Januvia and the sitagliptin family of products in the U.S.

Terms of the deal were not disclosed.

Shares +9.6% AH.